Browsing by Autor "S. Murillo-Lopez"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item type: Item ,
    Retinal vasculitis associated with intravitreal bevacizumab injection: A case report
    (Elsevier BV, 2025) S. Murillo-Lopez; Silvia Medina-Medina
    Anti-vascular endothelial growth factor drugs are the treatment of choice for macular edema due to venous occlusions. While rare, they have been associated with some uncommon adverse effects. We present a case of retinal vasculitis associated with bevacizumab in a72-year-old woman who presented to our clinic with sudden visual acuity loss in her left eye due to macular edema following central vein occlusion. She was treated with bevacizumab, with a minor inflammatory response that resolved with topical steroids. After 6 weeks, the macular edema recurred and a 2<sup>nd</sup> dose of bevacizumab was indicated, with a severe inflammatory reaction that resolved with periocular steroids and topical NSAIDs. Systemic vasculitis and infectious diseases were ruled out and treatment was switched to aflibercept with no adverse effects being reported.
  • Thumbnail Image
    Item type: Item ,
    Vasculitis retiniana asociada a inyección intravítrea de bevacizumab: reporte de caso
    (Elsevier BV, 2025) S. Murillo-Lopez; Silvia Medina-Medina
    Los fármacos anti-factor de crecimiento vascular endotelial son el tratamiento de elección para el edema macular secundario a oclusión venosa; aunque sus efectos secundarios han sido previamente descritos, estos suelen ser raros. A continuación, presentamos un caso de vasculitis retiniana asociada a bevacizumab en una paciente de 72 años que acudió a consulta por edema macular secundario a oclusión de vena central de la retina, por lo que fue tratada con bevacizumab intravítreo. Posteriormente presentó una respuesta inflamatoria mínima que fue resuelta con esteroides tópicos. Seis semanas después se detectó recurrencia del edema macular por lo que se aplicó una segunda dosis de bevacizumab, en esta ocasión con una respuesta inflamatoria severa que requirió tratamiento con esteroides paraoculares y antiinflamatorios no esteroideos tópicos. Se descartó la presencia de vasculitis sistémica y enfermedades infecciosas y se decidió cambiar el tratamiento intravítreo a aflibercept, con el que no se presentaron efectos adversos. Anti-vascular endothelial growth factor drugs are the treatment of choice for macular edema due to venous occlusions. While rare, they have been associated with some uncommon adverse effects. We present a case of retinal vasculitis associated with bevacizumab in a72-year-old woman who presented to our clinic with sudden visual acuity loss in her left eye due to macular edema following central vein occlusion. She was treated with bevacizumab, with a minor inflammatory response that resolved with topical steroids. After 6 weeks, the macular edema recurred and a 2 nd dose of bevacizumab was indicated, with a severe inflammatory reaction that resolved with periocular steroids and topical NSAIDs. Systemic vasculitis and infectious diseases were ruled out and treatment was switched to aflibercept with no adverse effects being reported.